Benjamin Besse, MD, PhD, discusses the main findings and next steps of the phase 1/1b CHRYSALIS-2 study in EGFR-mutated non–small cell lung cancer.
Benjamin Besse, MD, PhD, professor of medical oncology at Université Paris-Saclay and Head of Clinical Research at Gustave Roussy, discusses the main findings and next steps of the phase 1/1b CHRYSALIS-2 (NCT04077463) study which is evaluating the efficacy amivantamab (Rybrevant) and lazertinib (Leclaza) in patients with EGFR-mutated non–small cell lung cancer (NSCLC).
According to findings from the 101 patients enrolled in cohort D of the ongoing, phase 1/1b study presented at the 2020 ASCO Annual Meeting, MET+ by immunohistochemistry may be a predictive biomarker for response to this combination of amivantamab and lazertinib among patients with NSCLC who previously failed treatment with osimertinib (Tagrisso) and who are chemotherapy-naïve. This combination of amivantamab and lazertinib represents a potential chemotherapy-free option for this patient population.
0:08 | The next step for the study is to confirm the predictive value in other cohorts, a cohort with the combination, the same combination, but also a cohort only with amivantamab. Later, we will see what we can do with this predictive signature in the new landscape of the treatment if we have this combination first-line, if the MARIPOSA trial [NCT04487080] is positive, or if we have a new combination, like chemotherapy plus osimertinib.
0:40 | The key takeaways are that today, amivantamab is available only for a small subgroup of patients with EGFR mutated non–small cell lung cancer, in those patients with exon 20 insertion of EGFR. But given the activity of the combination in the other patients with more classical EGFR mutations, it is very likely that this combination will be in our hands [soon] to treat these patients either in the first-line, either maybe after failure of osimertinib, and it will be good to have a signature in this very near future to select the best patients for this treatment.